0001104659-24-066653.txt : 20240530 0001104659-24-066653.hdr.sgml : 20240530 20240530161556 ACCESSION NUMBER: 0001104659-24-066653 CONFORMED SUBMISSION TYPE: S-8 PUBLIC DOCUMENT COUNT: 5 FILED AS OF DATE: 20240530 DATE AS OF CHANGE: 20240530 EFFECTIVENESS DATE: 20240530 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Verastem, Inc. CENTRAL INDEX KEY: 0001526119 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 273269467 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-8 SEC ACT: 1933 Act SEC FILE NUMBER: 333-279826 FILM NUMBER: 241005635 BUSINESS ADDRESS: STREET 1: 117 KENDRICK STREET STREET 2: SUITE 500 CITY: NEEDHAM STATE: MA ZIP: 02494 BUSINESS PHONE: (781) 292-4200 MAIL ADDRESS: STREET 1: 117 KENDRICK STREET STREET 2: SUITE 500 CITY: NEEDHAM STATE: MA ZIP: 02494 S-8 1 tm2415840d1_s8.htm FORM S-8

 

As filed with the Securities and Exchange Commission on May 30, 2024

Registration No. 333-    

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S-8

 

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

Verastem, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   27-3269467
(State or other jurisdiction
of incorporation or organization)
  (I.R.S Employer Identification No.)
     
117 Kendrick St., Suite 500
Needham, MA
  02494
(Address of Principal Executive Offices)   (Zip Code)

 

Amended and Restated 2021 Equity Incentive Plan

(Full title of the plan)

 

Daniel Paterson
President and Chief Executive Officer
Verastem, Inc.

117 Kendrick St., Suite 500

Needham, MA 02494

(781) 292-4200

(Name, address, and telephone number, including area code, of agent for service)

 

With copies to:

Marko S. Zatylny

Ropes & Gray LLP

Prudential Tower

800 Boylston Street

Boston, MA 02199

(617) 951-7000

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨   Accelerated filer ¨
Non-accelerated filer x   Smaller reporting company x
    Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o

 

 

 

 

 

 

EXPLANATORY NOTE

 

This Registration Statement on Form S-8 is being filed to register an additional 3,200,000 shares under the Registrant’s Amended and Restated 2021 Equity Incentive Plan. Pursuant to General Instruction E to Form S-8, the Registrant incorporates by reference, except to the extent supplemented, amended or superseded by the information set forth herein, into this Registration Statement the entire contents of its Registration Statements on Form S-8 (File No. 333-257111) filed with the Securities and Exchange Commission on June 15, 2021.

 

 

 

 

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 8. Exhibits.

 

Exhibit   Description
4.1   Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Annual Report on Form 10-K filed by the Registrant on March 12, 2019)
4.2   Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Annual Report on Form 10-K filed by the Registrant on March 12, 2019)
4.3   Certificate of Amendment to the Restated Certificate of Incorporation of Verastem, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Registrant with the Securities and Exchange Commission on May 21, 2020)
4.4   Certificate of Amendment to the Restated Certificate of Incorporation of Verastem, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Registrant with the Securities and Exchange Commission on May 31, 2023)
4.5   Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.4 to Amendment No. 3 to the Registration Statement on Form S-1 filed by the Registrant with the Securities and Exchange Commission on January 13, 2012)
4.6   Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Registrant with the Securities and Exchange Commission on November 7, 2022)
4.7   Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Registrant with the Securities and Exchange Commission on January 25, 2023)
4.11   Amended and Restated 2021 Equity Incentive Plan (incorporated by reference to Appendix A of the Registrant’s Definitive Proxy Statement on Schedule 14A, filed by the Registrant with the Securities and Exchange Commission on April 12, 2024)
5.1   Opinion of Ropes & Gray LLP (filed herewith)
23.1   Consent of Ropes & Gray LLP (included in Exhibit 5.1)
23.2   Consent of Ernst & Young LLP (filed herewith)
24.1   Power of attorney (included on the signature page of this Registration Statement under the caption “Power of Attorney”)
107   Filing Fee Table (filed herewith)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Needham, Commonwealth of Massachusetts on May 30, 2024.

 

  VERASTEM, INC.
     
  By: /s/ Daniel Paterson
    Daniel Paterson
    President and Chief Executive Officer

 

POWER OF ATTORNEY

 

Each person whose signature appears below constitutes and appoints Daniel Paterson and Daniel Calkins, and each of them singly, either of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and other documents in connection therewith with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them singly, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

 

SIGNATURES   TITLE   DATE
/s/ Daniel Paterson   President, Chief Executive Officer and Director   May 30, 2024
Daniel Paterson   (Principal executive officer)    
         
/s/ Daniel Calkins   Chief Financial Officer   May 30, 2024
Daniel Calkins   (Principal financial and accounting officer)    
         
/s/ Paul A. Bunn, M.D.   Director   May 30, 2024
Paul A. Bunn, M.D.        
         
/s/ Robert Gagnon   Director   May 30, 2024
Robert Gagnon        
         
    Director   May 30, 2024
John H. Johnson        
         
/s/ Anil Kapur   Director   May 30, 2024
Anil Kapur        
         
/s/ Michael Kauffman   Director   May 30, 2024
Michael Kauffman, M.D., Ph.D.        
         
/s/ Michelle Robertson   Director   May 30, 2024
Michelle Robertson        
         
/s/ Eric Rowinsky, M.D.   Director   May 30, 2024
Eric Rowinsky, M.D.        
         
/s/ Brian Stuglik   Director   May 30, 2024
Brian Stuglik        
         
/s/ Karin Tollefson   Director   May 30, 2024
Karin Tollefson        

 

 

 

EX-5.1 2 tm2415840d1_ex5-1.htm EXHIBIT 5.1

 

Exhibit 5.1

 

  ROPES & GRAY LLP
PRUDENTIAL TOWER
800 BOYLSTON STREET
BOSTON, MA 02199-3600
WWW.ROPESGRAY.COM

 

 May 30, 2024

 

Verastem, Inc.

117 Kendrick Street, Suite 500

Needham, MA 02494

 

Ladies and Gentlemen:

 

This opinion letter is furnished to you in connection with the registration statement on Form S-8 (the “Registration Statement”), filed by Verastem, Inc., a Delaware corporation (the “Company”), on the date hereof, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), for the registration of 3,200,000 shares of Common Stock, $0.0001 par value per share, of the Company (the “Shares”). The Shares are issuable under the Company’s Amended and Restated 2021 Equity Incentive Plan (the “Plan”).

 

We are familiar with the actions taken by the Company in connection with the adoption of the Plan. We have examined such certificates, documents and records and have made such investigation of fact and such examination of law as we have deemed appropriate in order to enable us to render the opinions set forth herein. In conducting such investigation, we have relied, without independent verification, upon certificates of officers of the Company, public officials and other appropriate persons.

 

The opinions expressed below are limited to the Delaware General Corporation Law.

 

Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized and, when the Shares have been issued and sold in accordance with the terms of the Plan, the Shares will be validly issued, fully paid and nonassessable.

 

We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

 

  Very truly yours,
   
  /s/Ropes & Gray LLP
   
  Ropes & Gray LLP

 

 

 

 

EX-23.2 3 tm2415840d1_ex23-2.htm EXHIBIT 23.2

 

Exhibit 23.2

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Amended and Restated 2021 Equity Incentive Plan of Verastem, Inc. of our report dated March 14, 2024, with respect to the consolidated financial statements of Verastem, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2023, filed with the Securities and Exchange Commission.

 

/s/ Ernst & Young LLP

 

Boston, Massachusetts

 

May 30, 2024

 

 

 

EX-FILING FEES 4 tm2415840d1_ex-filingfees.htm EX-FILING FEES

 

Exhibit 107

 

CALCULATION OF REGISTRATION FEE

 

Form S-8

(Form Type)

 

Verastem, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered Securities

 

Security
Type
Security Class 
Title
Fee
Calculation
Rule
Amount
Registered (1)
Proposed
Maximum
Offering Price
Per Unit

Maximum
Aggregate
Offering
Price

 

Fee Rate Amount of Registration
Fee
Equity Common stock, $0.0001 par value per share Rule 457(c) and 457(h)(1)  3,200,000 $4.26 (2) $13,632,000 0.00014760 $2,012.08
Total Offering Amounts   $13,632,000   -
Total Fee Offsets (3)       -
Net Fee Due       $2,012.08

 

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers such additional shares of the Registrant’s common stock, par value $0.0001 per share (the “Common Stock”), as may be issued under the Registrant’s Amended and Restated 2021 Equity Incentive Plan (the “2021 Plan”) to prevent dilution from stock splits, stock dividends and similar transactions.
   
(2) Pursuant to Rules 457(c) and 457(h)(1) under the Securities Act, the proposed maximum offering price per share and the maximum aggregate offering price for the shares have been calculated solely for the purpose of computing the registration fee on the basis of the average high and low prices of the Common Stock as reported by the Nasdaq Capital Market on May 28, 2024 to be $4.26 and $13,632,000, respectively.
   
(3) The Registrant does not have any fee off-sets.

 

 

 

GRAPHIC 5 tm248659d1_ex5-1img001.jpg GRAPHIC begin 644 tm248659d1_ex5-1img001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#V#Q)XOTWP MJUHNH"=FNRPB$2@DE=N>I']X5!I7CO1]6U&.P47%M<29\M+J,)O([#DY-16JBK+S,'.5WY6.QU'4 M+72K":]O95BMXEW,S&N:TOXCZ/J>I0V1MM0LVG;;#+=Q*B2GL%(8YS67\921 MX.M5R<-J$08>HVOQ5GXHQHOAW3650#'J=OL('W>3THC%-*_42 .I'H"4QRRB)1$ 3N()[D>AJKHWC&QUR_^QV]I?Q/L+[IX0JX'ODUSGQA_P"0 M'H__ &%(O_06KT6ILE%,I-N;78Y?7O'>EZ#J'V!H+V]N@NYXK*-9#&/]K+#% M;&BZU9:_IJ7]BY:)B5(;AD8=5([&N'^'O[SQWXZD?YG%ZJACU W2\?H/RK5^ M'ZA'\3JH 4:]= =!]RJE%)$QFVUYW_ [.BBBLC8\J^+G_(P^#/^ON3_ -#A MK;^(?_(3\'C_ *C<'\ZP/C)')+K'A*.*0Q2/<2JL@&=I+18/X5/=Z;J6@>,? M#USX@U%M:MY[G[/;EAL-O,V-K;1P:Z$M(OU.63]Z2]"]\9?^10L_^PC%_P"@ MO5SXI?\ (MV/_83M_P"9JG\9?^10L_\ L(Q?^@O5SXI?\BW8_P#83M_YFIC] MGYE3WEZ(E^*W_).-4^L7_HQ:J?$[_DG2?]=K?_T(5;^*W_).-4^L7_HQ:H#P M7K^M+81Z]KT=QIL3I,UM%%MWXZ FB-DDWW"=W)I+=#/C#_R ]'_["D7_ *"U M>BUYO\959_#NE*C;&.I1@-Z':_-=)X?T+7=,OWGU/Q'+J4!B*B%H50!L@[LC MV!'XTFO<7S*3?M'IV,'20GAOXLZM92?)!KD2W4#-T,BD[E_-F/Y5W-GI]I8& MX-K L1N)FGEV_P ;MC+'W.!7+_$;P[<:YH"7.G_+J>GR?:+=A][CJH^N ?J! M6UX7UR+Q%X#_\ L-P?SK#^+G_(P^#/^ON3_P!#AK<^(?\ R$O!_P#V M&X/YUNMH_,YGO/Y?H5/C+_R*%G_V$8O_ $%ZN?%+_D6['_L)V_\ ,U7^,4$L MO@N*2.-G2"]CEE*C.U<,,G\2/SJ/XB:MI^J:+I%K87D%S/< M#M1':/S'/>7HC1^*W_).-4^L7_HQ:ZVT_P"/.#_KFO\ *N2^*W_).-4^L7_H MQ:ZVT_X\X/\ KFO\JS?PHT7QOT1P'QA_Y >C_P#84B_]!:O1:\Y^,1"Z#I#, M0 -4C))[?*U=S;ZQIEW,(;;4;6:4]$CF5B?P!IOX%\Q1?OR^15T;Q%::W>ZI M:6\4N 6&>G/3BN&^'-_+:^,O$7AR(*+""YN9HQW4B1% ^F*N>#+ MNVTOQ=XRMK^XBMIGO_/19G"ED.XAAGJ,$?G69\.H9+KXB^)-7@0R:?++XNH M;22"]L#*0D)NX#&K'L 1[XS6!X6L_",MDWB'1-'%NT&]=VS M$@P.0!DCD&M/QQ=_8O!6K2YP6@,0_P"!G;_6L3X;MY US2V 'D70D"^SK_\ M8T[NPFE?8T(],\+>/[*'6)]+6?.45Y04&P=T8B(+%N5@& .>3DYK)^&@^QZ5JNFR$AK'4)4Y[+@?X&KGP[3=X9>](P; MZ[FN>?=L?^RT-O8$E>YUE%%%268_BO3_ .U/"NI6@Y9X"R8_O+\R_J!7->"[ MZ;Q!J5QXGO\ $,:0)96X8X!Z%SGOEJUO&^K&QT?[# VV\U'_ $> YZ%F52?R M>N$N_,TGPUK/AN1V/V#487@)ZF)V!'^?>F2]ST/QO_R)6K_]>[58TBU@O?". MFV]S"DT+V<(:-UR&^1>HJOXW_P"1*U?_ *]VJC-KL_A[P5I=\FGF[@2SB,Q$ MH38-J@=CG.:!]1GQ%ACM_AW>00HL<48A5$48"@.H J+XB_\B.@]9H/YBF>. M+T:G\+)+X(8Q/=;3$C83T88 M."1Z&@3-GXH,Q\(?9U^]&4#Z!1_[-4GC] M3R]3^1J-O]%^,JG&!=Z9CZD-_]A0'4CN9TT/6_&3#Y%FL M8[Q/][:R'\VQ72^%K3[#X5TJWQ@K;(6^I&3^I-<5\3()?[7L(X@?^)I#]A8C MVE1A_,UZ6JA%"J,*!@"@:W%HHHI#///B+_R,_@[_ *_&_P#0XJJ?$NQ:/6=, MNHQA;XK:R^F5D5E/\_RK1^(]M(MYH&K$?Z-IUSYDY] 7B_P-1>/[B#Q#96.E MZ5.ES=^8]T/);)54C<_ADD"F2^IT?C?_ )$K5_\ KW:L?Q!_R1__ +A\'_LE M6M4NVUSX7W%W$"[SV&\@==P'S#\P:Q]9UK3;CX2B&*]A:4V4,?E[OFW#;D8_ M T Q?$7_ "12V_Z\[3^:5?\ B+_R(R?]=H/YBJ'B+_DBEM_UYVG\TJ_\1?\ MD1D_Z[0?S% ">+(;N^\9^';:PGC@N(DN)UDD3>!PHZ?G5&[M=6L/'_AN[U2] M@N3*9H%,47EX&SH?7DULL?/^*J#&5M]()^A:3_"HO'7[FZ\-7G01:K$I/LV< M_P J *WC_P#Y#/A3_L(K_-:[FN&\?_\ (9\*?]A%?YK7CE0,K?4'@U6M-%TJPF\ZSTRRMI<;=\,"HV/3('2BB@"Q#:6UO M:BU@MXHK< @1(@5 #U&!QW-9_P#PB_A__H!:9_X"1_X444 7I+"SFLA92VD$ MEH %$#1@H .@VXQ@8%+0>1=6T,\.0?+E0,N1TX-%% #A:VZW370@B%P MRA&E"#>5]">N/:DN;2VO%1;JWBG5'#J)4#!6'0C/0^]%% "7%E:7;Q/